Clinical TrialsThe FASCINATE-3 Ph3 program for denifanstat in F2/F3 MASH patients has started, indicating progress in clinical trials.
Market ExpansionSGMT's expansion into acne is considered an upside, given the large opportunity and mechanistic rationale.
Market OpportunitiesSGMT is considered an attractive play on the broader NASH space, trading at a relative discount to competitors and highly levered to broader NASH market sentiment.